Effect of adding rituximab to intensified and high dose chemotherapy (HDC) with ASCT as first line treatment in stage III-IV at intermediate-high (IH) and high risk (HR) diffuse large B-cell lymphoma

Autor:	Vitolo, U., Cabras, Mg, Rossi, G., Liberati, Am, ANNALISA CHIAPPELLA, Levis, A., Pavone, E., Angelucci, E., Botto, B., Ciccone, G., Freilone, R., Novero, D., Orsucci, L., Palumbo, I., Pogliani, E., Pregno, P., Scalabrini, Dr, Salvi, F., Tonso, A., Tucci, A., Gallo, E.
Rok vydání:	2005
Zdroj:	Publons
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::014b701b6e7ce30b86e26c5788683ed3 http://hdl.handle.net/11391/1011674 Zobrazit plný text záznamu